Why GLP-1 optimism has put Hims & Hers Health (HIMS) in focus

Recent attention on Hims & Hers Health (HIMS) stems from optimism around its branded GLP-1 and peptide offerings, alongside an acquisition-driven push to grow its consumer wellness platform.

That growth angle has sharpened investor interest in how far revenue expectations can stretch, but evolving FDA scrutiny on peptide safety keeps the outlook balanced rather than one-sided.

At a share price of $36.07, Hims & Hers Health has seen strong recent momentum, with a 30 day share price return of 32.76% and a 90 day gain of 82.63%, even though the 1 year total shareholder return is down 29.61% and the 3 year total shareholder return is very large.

If GLP 1 enthusiasm has you rethinking your health exposure, it can be useful to compare Hims & Hers Health with other healthcare focused AI opportunities using the 40 healthcare AI stocks

After such a sharp move in Hims & Hers Health on GLP 1 enthusiasm, yet with only 2 of 6 valuation checks passed and the stock trading above analyst targets, does the current balance of risk and reward still lean toward buyers?

Most Popular Narrative: 79.2% Undervalued

The most followed narrative on Hims & Hers Health values the stock at a fair value of $173.02, well above the last close of $36.07. This puts a strong spotlight on how ambitious the underlying assumptions are.

Even after deliberately moderating assumptions relative to the company’s full potential, the implied valuation remains meaningfully above current levels. The disconnect between execution momentum and market pricing suggests a compelling opportunity both in short and long term.

Want to see what is driving that gap between $36.07 and $173.02? According to Deep_Insights, everything hinges on rapid revenue expansion, improving margins and a premium future earnings multiple. Curious how those moving parts combine into one aggressive fair value story? The full narrative lays out the exact roadmap, step by step.

Result: Fair Value of $173.02 (UNDERVALUED)

However, this relies heavily on GLP 1 adoption and ambitious revenue and margin assumptions, so tighter FDA action or slower uptake could quickly undercut the Hims & Hers Health narrative.

Another view on Hims & Hers Health valuation

While the community narrative sees Hims & Hers Health as deeply undervalued, the SWS DCF model tells a very different story, with a fair value estimate of $3.86 against the current $36.07 share price, implying the stock screens as expensive. Which story do you trust more: the growth narrative or the cash flow math?

For a closer look at how that cash flow view is built, including the key inputs behind the gap to the current price, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hims & Hers Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the split views on Hims & Hers Health have you undecided, now is a good time to review the underlying data yourself and move fast to form a clear stance using the 1 key reward and 1 important warning sign.

Looking for more ideas beyond Hims & Hers Health?

If the Hims & Hers Health debate sharpened your thinking, do not stop here. Broaden your watchlist with other focused ideas that match your risk and return preferences.

• Spot potential turnaround stories early by checking out financially stronger small caps using the 20 elite penny stocks with strong financials.
• Zero in on companies that combine quality fundamentals with room for appreciation through the 44 high quality undervalued stocks.
• Prioritise resilience in choppy markets and focus on steadier profiles with the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.